Trial reportThe journal of headache and pain2022
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab.
Trial report in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03773562 (Imaging the Migraine Brain Pre- and Post-Erenumab), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imaging the Migraine Brain Pre- and Post-Erenumab: an MRI Study to Identify Functional and Structural Changes That Correlate With Patient Improvement
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Imaging the brain and vascular reactions to headache treatments: a systematic review.The journal of headache and pain · 2023Pooled it
- Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study.The journal of headache and pain · 2024Trial
- The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN).Journal of neurology · 2023Trial
- Multimodal serum and MRI signatures of neuroaxonal injury in high-frequency migraine.The journal of headache and pain · 2026Article
- Identifying neural oscillation and phase synchronization abnormalities in migraine and their predictive values in transcranial magnetic stimulation.Journal of oral & facial pain and headache · 2026Article
- Atogepant modulates brain connectivity in episodic migraine: a longitudinal exploratory fMRI study.Frontiers in neurology · 2026Article
- Accelerated brain ageing in migraine: a multilevel MRI-based brain-age modelling study.Brain communications · 2026Article
- CGRP and Migraine: Real-World Insights and Future Therapeutic Directions.Annual review of medicine · 2026Review
- Increased integration and synergy in EEG- and fNIRS-based data in migraine patients after a three-month treatment with galcanezumab: relations with long-term clinical outcome.Scientific reports · 2025Article
- 3T MRI thalamic segmentation reveals no macrostructural changes in interictal episodic migraine without aura compared to healthy controls.The journal of headache and pain · 2025Article
- Article
- Periaqueductal gray functional connectivity abnormalities associated with acute post-traumatic headache.Journal of neurology · 2025Article
- Effects of acute sleep deprivation on the brain function of individuals with migraine: a resting-state functional magnetic resonance imaging study.The journal of headache and pain · 2025Article
- Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data.Current pain and headache reports · 2024Review
- Disrupted topologic efficiency of white matter structural connectome in migraine: a graph-based connectomics study.The journal of headache and pain · 2024Article
- Multilayer network changes in patients with migraine.Brain and behavior · 2023Article
- The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.The journal of headache and pain · 2023Article
- Parahippocampus hypertrophy drives gray matter morphological alterations in migraine patients without aura.The journal of headache and pain · 2023Article
- Connectivity Analysis in EEG Data: A Tutorial Review of the State of the Art and Emerging Trends.Bioengineering (Basel, Switzerland) · 2023Review
- Artificial Intelligence for Automatic Pain Assessment: Research Methods and Perspectives.Pain research & management · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine involves central and peripheral nervous system mechanisms. Erenumab, an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody with little central nervous system penetrance, is effective for migraine prevention. The objective of this study was to determine if response to erenumab is associated with alterations in brain functional connectivity and pain-induced brain activations.
methodsAdults with 6-25 migraine days per month during a 4-week headache diary run-in phase underwent pre-treatment brain functional MRI (fMRI) that included resting-state functional connectivity and BOLD measurements in response to moderately painful heat stimulation to the forearm. This was followed by two treatments with 140 mg erenumab, at baseline and 4 weeks later. Post-treatment fMRI was performed 2 weeks and 8 weeks following the first erenumab treatment. A longitudinal Sandwich estimator analysis was used to identify pre- to post-treatment changes in resting-state functional connectivity and brain activations in response to thermal pain. fMRI findings were compared between erenumab treatment-responders vs. erenumab non-responders.
resultsPre- and post-treatment longitudinal imaging data were available from 32 participants. Average age was 40.3 (+/- 13) years and 29 were female. Pre-treatment average migraine day frequency was 13.8 (+/- 4.7) / 28 days and average headache day frequency was 15.8 (+/- 4.4) / 28 days. Eighteen of 32 (56%) were erenumab responders. Compared to erenumab non-responders, erenumab responders had post-treatment differences in 1) network functional connectivity amongst pain-processing regions, including higher global efficiency, clustering coefficient, node degree, regional efficiency, and modularity, 2) region-to-region functional connectivity between several regions including temporal pole, supramarginal gyrus, and hypothalamus, and 3) pain-induced activations in the middle cingulate, posterior cingulate, and periaqueductal gray matter.
conclusionsReductions in migraine day frequency accompanying erenumab treatment are associated with changes in resting state functional connectivity and central processing of extracranial painful stimuli that differ from erenumab non-responders.
trial registrationclinicaltrials.gov (NCT03773562).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.